Avalo Therapeutics, Inc. (AVTX) Operating cash flow 2016–2025
Avalo Therapeutics, Inc. (AVTX) annual operating cash flow history from SEC filings — net cash provided by operating activities each fiscal year.
-$51.5MFY2025 · since FY2016: -$14.6M → -$51.5M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | -$51.5M | -4.9% |
| FY2024 | -$49.1M | -59.9% |
| FY2023 | -$30.7M | -14.7% |
| FY2022 | -$26.8M | +62.3% |
| FY2021 | -$70.9M | -74.9% |
| FY2020 | -$40.5M | -111.9% |
| FY2019 | -$19.1M | -511.7% |
| FY2018 | -$3.1M | -124.9% |
| FY2017 | $12.6M | +186.3% |
| FY2016 | -$14.6M | — |
Source: SEC XBRL filings · For reference only · Not investment advice